Intuitive Surgical
ISRGWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $420.95 (close on November 18) and with the other assumptions at their starting point, Intuitive Surgical's sales would need to grow 33.1% a year for ten years; over its last decade, the median was 16.6%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 2,384 | — | 38.1% |
| 12/2016 | 2,706 | 13.5% | 41.7% |
| 12/2017 | 3,138 | 16.0% | 40.5% |
| 12/2018 | 3,724 | 18.7% | 39.2% |
| 12/2019 | 4,478 | 20.3% | 38.2% |
| 12/2020 | 4,358 | −2.7% | 33.2% |
| 12/2021 | 5,710 | 31.0% | 39.8% |
| 12/2022 | 6,222 | 9.0% | 33.6% |
| 12/2023 | 7,124 | 14.5% | 33.1% |
| 12/2024 | 8,352 | 17.2% | 36.2% |
| 12/2025 | 10,065 | 20.5% | 37.1% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Intuitive Surgical files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 17.2% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 36.2% of sales.
- Working capital needed to grow: $11.5 per $100 of new sales.
- Capital spending: 8.6% of sales.
- Stock pay to employees: 18.1% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- It has more cash than debt.
- It makes $36 of operating profit for every $100 it sells, before stock pay; the median is $18.
- Its sales grew 15.5% a year on average over 10 years, from $2.4 billion to $10.1 billion; the median of grinboss companies is 6.6%.
- It sold more than the year before in 9 of the last 10 years.
Against
- Its stock pay to employees is high: 18.1% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
- Its margin has fallen over these years, from 40% to 36%.
- It needs to invest a lot: its capital spending takes 8.6% of its sales every year, more than the median (3.3%).
- Its share price amplifies the market's moves: a five-year beta of 1.29; the median is 0.94.
Next results: January 28, 2027.
Other companies in its sector (Health Care)
Johnson & Johnson (JNJ) · Labcorp (LH) · Lilly (Eli) (LLY) · McKesson (MCK) · Medtronic (MDT) · Merck & Co. (MRK) · Moderna (MRNA) · Mettler Toledo (MTD) · All companies
Loading the model…